These include more complex molecular formats developed using Genmab's DuoBody technology. Genmab and Lonza have a longstanding relationship, having worked together on multiple antibody-based programs since 2002. Karen Fallen, head of Mammalian and Microbial Development and Manufacturing, Lonza Pharma & Biotech, said, "Extending this trusted relationship with Genmab is a great motivation for our teams who have been working together for a number of years. Genmab's extensive pipeline is an opportunity for us to combine the speed and flexibility of our Ibex Solutions with the know-how needed to manufacture pioneering molecular formats."